Risperidone dose for schizophrenia

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance

“…Further, the choice should take into account availability, affordability and sustainability of provision in the long term, in relation to the setting of care. The therapeutic dose of risperidone may vary between 2 and 10 mg/day, and a maintenance dose of 4 to 6 mg/day is usually required [ 35 , 39 ], while the dose of olanzapine may vary between 5 and 20 mg/day, and the maintenance dose required is usually 10 mg/day [ 35 ].…”

Empirical evidence about inconsistency among studies in a pair‐wise meta‐analysis

“…As a contrasting example, we re‐analysed data from a continuous outcome meta‐analysis combining four studies to assess the standard lower dose of risperidone in comparison with any dose with respect to the mental state of schizophrenia patients (Li et al, ). This meta‐analysis has a mean study size of 103 patients.…”

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance

“…Further, the choice should take into account availability, affordability and sustainability of provision in the long term, in relation to the setting of care. The therapeutic dose of risperidone may vary between 2 and 10 mg/day, and a maintenance dose of 4 to 6 mg/day is usually required [ 35 , 39 ], while the dose of olanzapine may vary between 5 and 20 mg/day, and the maintenance dose required is usually 10 mg/day [ 35 ].…”

Empirical evidence about inconsistency among studies in a pair‐wise meta‐analysis

“…As a contrasting example, we re‐analysed data from a continuous outcome meta‐analysis combining four studies to assess the standard lower dose of risperidone in comparison with any dose with respect to the mental state of schizophrenia patients (Li et al, ). This meta‐analysis has a mean study size of 103 patients.…”

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance

“…Further, the choice should take into account availability, affordability and sustainability of provision in the long term, in relation to the setting of care. The therapeutic dose of risperidone may vary between 2 and 10 mg/day, and a maintenance dose of 4 to 6 mg/day is usually required [ 35 , 39 ], while the dose of olanzapine may vary between 5 and 20 mg/day, and the maintenance dose required is usually 10 mg/day [ 35 ].…”

Empirical evidence about inconsistency among studies in a pair‐wise meta‐analysis

“…As a contrasting example, we re‐analysed data from a continuous outcome meta‐analysis combining four studies to assess the standard lower dose of risperidone in comparison with any dose with respect to the mental state of schizophrenia patients (Li et al, ). This meta‐analysis has a mean study size of 103 patients.…”